NURO
by Access Infinity

Access Infinity

Nuro is a comprehensive data platform that brings together HTA Insights, Evidence, Pricing Intelligence, & other critical business insights all under one roof.

Explore relationships between different datasets (e.g. HTA outcome vs. price)

- Easily correlate evidence submitted with HTA outcomes with and prices achieved
- Regulatory insights & analytics capabilities for 30+ countries
- HTA insights for markets representing 90% of global pharma sales

The fastest & most comprehensive analogue analysis in the world

+450 datpoints captured for every single approved product

Match against +150 product characteristics & criteria in seconds

Identify an exhaustive list of analogues with a consistent & repeatable approach

Wheel segments: PIVOTAL STUDIES, HTA INSIGHTS, PRICING DATA, PRODUCT CHARACTERISTICS, REGULATORY INTELLIGENCE

Regulatory approval labels: REGULATORY APPROVAL DATE, ORPHAN DESIGNATION, BREAKTHROUGH DESIGNATION, PRIORITY REVIEW, FAST TRACK DESIGNATION, ACCELERATED REVIEW, EMA (EU), FDA (US), PMDA (JP), MFDS (KR), HC (CN), TGA (AU), NMPA (CN), ANVISA (BR)

INTRODUCING THE ALL-IN-ONE SOLUTION

### Answer complex business questions with a single platform...

? What is the impact of a competitor launch or indication extension on price?

? How can I use competitive insights to benchmark time to access?

? Which products had their ASMR or Benefit Assessment scores overturned after reassessments?

HOW DO WE DO IT?

What is the impact on price of launching in a 3rd indication for a non-orphan, biologic product approved for autoimmune conditions?

Start with all EMA/FDA approved products

Filter for autoimmune indications

Approved in the last 10 years

Products approved in ≥ 3 indications

Filter for non-orphan indications only

Filter for Biologics only

8 analogues

Take a systematic 'funneling' approach to identifying analogues to make it consistent and repeatable

Making connections between critical market access data points

Evidence insights
- Inform a minimum reimbursable profile using current evidence benchmarks
- Compare evidence packages submitted with HTA outcomes

HTA outcomes
- Determine likely HTA outcomes based on evidence available
- Correlate HTA outcomes to list prices achieved

Pricing insights
- Compare cost of treatment across all major markets
- See the impact of indication extensions on list price

Who are we?

Insight happens when data meets expertise

We are a pricing and market access consultancy that combines business intelligence data and human expertise to help pharma companies get products to market.

Access Infinity

Consulting
The critical support you need to develop a successful value assessment and launch strategy.

Products
Cloud-based apps for rapid business intelligence, KPI tracking, access and evidence planning.

"I found Nuro to be incredibly useful to find analogues and price benchmarks when I'm asked to do quick turnaround assessments. I haven't come across any other solution that comes close."

Senior Director Market Access, UCB

You're in good company

Pfizer · GILEAD · Merck · janssen · Otsuka · astellas · gsk GlaxoSmithKline